

11th May, 2023

Ref:- GHL/2023-24/EXCH/07

The General Manager Dept. of Corporate Services BSE Limited, P J Towers, Dalal Street, Mumbai - 400 001

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Monitoring Agency Report for the quarter ended March 31, 2023

Dear Sir,


Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed herewith the Monitoring Agency Report, towards utilization of proceeds of Initial Public Offer of the Company for the quarter ended March 31, 2023, issued by CRISIL Ratings Limited.

You are requested to take the above information on your record.

For Global Health Limited

Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035

Encl: a/a



Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319



Monitoring Agency Report for Global Health Limited for the quarter ended March 31, 2023



CRL/MAR/GDS6353/2022-23/1014

May 11, 2023

To Global Health Limited Medanta – Mediclinic, E-18, Defence Colony, New Delhi-110024

Dear Sir,

Monitoring Agency Report for the quarter ended March 31, 2023 - in relation to the proceeds raised through Initial Public Offer ("IPO") of Global Health Limited ("the Company")

Pursuant to Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("**SEBI ICDR Regulations**") and Monitoring Agency Agreement dated October 22, 2022, we hereby enclose the Monitoring Agency Report, issued by CRISIL Ratings Limited, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended March 31, 2023.

Request you to kindly take the same on records.

Thanking you, For and on behalf of CRISIL Ratings Limited

Sushant Sarode Director, Ratings (LCG)



Report of the Monitoring Agency (MA)

Name of the issuer: Global Health Limited

For quarter ended: March 31, 2023

Name of the Monitoring Agency: CRISIL Ratings Limited

(a) Deviation from the objects: Not applicable

(b) Range of Deviation: Not applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/certifications/statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature: Name and designation of the Authorized Signatory: Sushant Sarode Designation of Authorized person/Signing Authority: Director, Ratings (LCG)

CRISIL Ratings Limited (A subsidiary of CRISIL Limited) Corporate Identity Number: U67100MH2019PLC326247



1) Issuer Details:

Name of the issuer:	Global Health Limited
Names of the promoter:	Dr. Naresh Trehan
Industry/sector to which it belongs:	Healthcare - Hospital
2) Issue Details	
Issue Period:	Thursday, November 3, 2022 to Monday, November 7, 2022
Type of issue (public/rights):	Initial Public Offer (IPO)
Type of specified securities:	Equity Shares
IPO Grading, if any:	NA
Issue size:	Rs 22,055.70 million {Issue size comprises of fresh issuance/gross proceeds of Rs 5,000 million (net proceeds of Rs 4,767.01 million*) and an offer for sale of Rs 17,055.70 million}

*CRISIL Ratings shall be monitoring the net proceeds amount.

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	Management undertaking, Statutory Auditor Certificate*, Final Offer Document, Bank Statements	No comments	Yes



Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether shareholder approval has been obtained in case of material deviations from expenditures disclosed in the Offer Document?	NA	NA	No comments	NA
Whether the means of finance for the disclosed objects of the issue has changed?	No	Management undertaking, Final Offer	No comments	No
Is there any major deviation observed over the earlier monitoring agency reports?	NA	Document	No comments	NA
Whether all Government/statutory approvals related to the object(s) have been obtained?	NA		No comments	NA
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Yes		No comments	Yes
Are there any favorable events improving the viability of these object(s)?	No	Management undertaking	No comments	No
Are there any unfavorable events affecting the viability of the object(s)?	No		No comments	No
Is there any other relevant information that may materially affect the decision making of the investors?	No		No comments	No

NA represents Not Applicable

*Statutory Auditor Certificate issued by M/s Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration Number:001076N/N500013).

CRISIL Ratings Limited (A subsidiary of CRISIL Limited) Corporate Identity Number: U67100MH2019PLC326247

Registered Office: CRISIL House, Central Avenue, Hiranandani Business Park, Powai, Mumbai - 400076. Phone: +91 22 3342 3000 | Fax: +91 22 3342 3001



4) Details of object(s) to be monitored:

i. Cost of the object(s):

	Item co Head	Source of information/	Original cost	Revised		Comments of the Board of Directors		
Sr. No.		certification considered by MA for preparation of report	ered by Offer for Document) ration (Rs in		Comment of the MA	Reason of Cost revision	Proposed financing option	Particulars of firm arrange- ments made
1	Investment in two of Subsidiaries of Company, Global Health Patliputra Private Limited ('GHPPL') and Medanta Holdings Private Limited ('MHPL'), in the form of debt or equity for repayment/prepayment of borrowings, in full or part, of such Subsidiaries	Management undertaking, Statutory Auditor Certificate*, Final Offer Document, Bank Statements	3,750.00	NA	No comments	NA	NA	NA
2	General Corporate Purposes (GCP)#	Management undertaking, Statutory Auditor Certificate*, Final Offer Document, Bank Statements	1,017.01	NA	No comments	NA	NA	NA
	Total	-	4,767.01	-	-	-	-	-

*Statutory Auditor Certificate issued by M/s Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration Number:001076N/N500013).

#The amount for general corporate purposes does not exceed 25% of the Gross Proceeds from the Fresh Issue.

CRISIL Ratings Limited (A subsidiary of CRISIL Limited) Corporate Identity Number: U67100MH2019PLC326247

Registered Office: CRISIL House, Central Avenue, Hiranandani Business Park, Powai, Mumbai - 400076. Phone: +91 22 3342 3000 | Fax: +91 22 3342 3001



ii. **Progress in the object(s):**

		Source of information / certifications	Amount as		unt utiliz in millio				Comments of the Board of Directors	
Sr. No.	Item Head#	considered by Monitoring Agency for preparation of report	proposed in the Offer Document (Rs in million)	As at beginning of the quarter	During the quarter	At the end of the quarter	Total unutilized amount (Rs in million)	Comments of the Monitoring Agency	Reasons for idle funds	Proposed course of action
1	Investment in two of Subsidiaries of Company, GHPPL and MHPL, in the form of debt or equity for repayment/ prepayment of borrowings, in full or part, of	Management undertaking, Statutory Auditor Certificate*, Final Offer Document, Bank Statements	3,750.00	_	_	_	3,750.00^	No proceeds were utilized towards this object during the reported quarter	No Comments	No Comments
2	General Corporate Purposes (GCP)	Management undertaking, Statutory Auditor Certificate*, Final Offer Document, Bank Statements	1,017.01	-	-	_	1,017.01	No proceeds were utilized towards this object during the reported quarter	No Comments	No Comments
	Total		4,767.01	-	-	-	4767.01	-	-	-

* The company has provided board resolution dated March 27, 2023 wherein Board has approved the investment in subsidiary companies.

^ This amount has been utilised in first week of April 2023 in line with objects of offer.

*Statutory Auditor Certificate issued by M/s Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration Number:001076N/N500013).

CRISIL Ratings Limited (A subsidiary of CRISIL Limited) Corporate Identity Number: U67100MH2019PLC326247

Registered Office: CRISIL House, Central Avenue, Hiranandani Business Park, Powai, Mumbai - 400076. Phone: +91 22 3342 3000 | Fax: +91 22 3342 3001 www.crisilratings.com



#Brief description of objects:

Object of the Issue	Description of objects as per the offer document filed by the issuer
Investment in two of the	1. GHPPL and MHPL have entered into various borrowing
Subsidiaries of Company,	arrangements with banks and financial institutions including
GHPPL and MHPL, in the form of debt or equity for	borrowings in the form of term loans and non-fund based working capital facilities
repayment/pre-payment of	2. Company intends to utilize ₹3,750.00 million of the Net Proceeds
borrowings, in full or part, of	towards repayment or prepayment of borrowings, in full or part,
such Subsidiaries	availed by GHPPL and MHPL in part or full, by investing in
	GHPPL and MHPL through debt or equity infusion.
General Corporate Purposes	The general corporate purposes for which the Company proposes to utilize Net Proceeds include: 1. strategic initiatives, 2. funding growth opportunities, including acquisitions 3. meeting exigencies, 4. brand building, 5. investments into Subsidiaries of the Company and any other purpose as may be approved by Board of the Company or a duly appointed committee from time to time, subject to compliance with applicable laws. The quantum of utilization of funds towards each of the above purposes will be determined by Board of the Company, based on the amount actually available under this head and the business requirements of Company and other relevant considerations, from time to time.

S. No.	Type of instruments and name of the entity invested in	Amount invested® (Rs in million)	Maturity date	Earning# (Rs in million)	Return on Investment (%)	Market Value as at the end of the quarter^ (Rs in million)
1	ICICI Bank FD 16576573	9.71	Jun 27, 2023	0.14	5.50	9.85
2	ICICI Bank FD 114810005169	1,250.00	April 6, 2023	4.71	5.50	1,254.71
3	ICICI Bank FD 114810005170	1,274.65	April 21, 2023	5.02	5.75	1,279.67
4	HDFC Bank FD 50300771591529	2,309.00	April 4, 2023	1.20	4.75	2,310.20
	Total	4,843.37	_	11.07	-	4,854.44

iii. Deployment of unutilised IPO proceeds:

[®]As per management undertaking and Statutory Auditor Certificate issued by M/s Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration Number:001076N/N500013), unutilized funds of Rs 4,843.37 million including interest earned of Rs 75.97 million and provisional amount transferred to monitoring account of Rs. 4,767.40 million** subject to finalization of issue expense

The difference of 0.39 million is owing to transfer of this additional amount from public offer bank account to monitoring agency bank account since the amount of 232.99 netted of as total share issue expenses includes certain provisions which are yet to be settled.

**Earnings/interest on fixed deposit has been determined from deposit date till 31 March 2023. The interest calculation is before TDS applicability.*

[^]Market value at end of the quarter is the sum total of [']Amount Invested' and ^Earnings/Interest'.





iv. Delay in implementation of the object(s) -

	Completi	on Date		Comments of the Board of Directors	
Object(s)	As per the Offer Document	Actual	Delay (no. of days/ months)	Reason of delay	Proposed course of action
		Ν	IA		

Note: As per the implementation schedule in Offer Document, entire net proceeds amounting to Rs.4,767.01 million is to be utilised by FY23 however as per footnote to schedule "In the event the estimated utilization of the Net Proceeds is not completed in Fiscal 2023, the remaining amount shall be utilized in Fiscal 2024, as may be determined by the Board, in accordance with applicable laws."

As per management undertaking, during the quarter ended March 31, 2023, the Board of Directors of the Company^{*} has authorized various heads under which the IPO proceeds will be utilized and accordingly IPO proceeds to the extent of Rs 3,750 million has been utilized in the month of April 2023 and remaining would be utilised in line with the board approval and objects mentioned in the IPO.

**Company has provided board resolution dated March 27, 2023 wherein Board has approved the Investment in subsidiary companies.*

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document: Not Applicable^

As per management undertaking and Statutory Auditor Certificate issued by M/s Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration Number:001076N/N500013),



Disclaimers:

- a) This Report is prepared by CRISIL Ratings Limited (hereinafter referred to as "Monitoring Agency" / "MA" / "CRL"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.
- b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.
- c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.
- e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.
- f) The MA report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRL providing or intending to provide any services in jurisdictions outside India, where it does not have the necessary licenses and/or registration to carry out its business activities referred to above.
- *g)* Access or use of this report does not create a client relationship between CRL and the user.
- *h)* CRL is not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing this report, MA has not taken into consideration the objectives or particular needs of any particular user.
- *i)* It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be a basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).
- *j)* The report comprises professional opinion of CRL as of the date they are expressed, based on the information received from the issuer and other sources considered reliable by CRL. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. The report does not constitute statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions.
- *k)* Neither CRL nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents guarantee the accuracy, completeness or adequacy of the report, and shall not have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. CRL and each aforesaid party disclaims any and all express or implied



warranties, including but not limited to any warranties of merchantability, suitability or fitness for a particular purpose or use or use. In no event shall CRL or any aforesaid party be liable to any user for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

- *l)* CRL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with the preparation of this report. CRL has in place a code of conduct and policies for managing conflict of interest.
- *m*) Unless required under any applicable law, this report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRL.
- *n)* By accepting a copy of this Report, the recipient accepts the terms of this Disclaimer, which forms an integral part of this Report.